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A phase I and pharmacological study of the matrix
metalloproteinase inhibitor BB-3644 in patients with solid tumours
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BB-3644 is an oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI) structurally related to marimastat and BB-94. It is also
410-fold more active than marimastat in inhibiting the processing of cell-bound TNF-a. Preclinical studies suggested a favourable
toxicity profile when compared to marimastat, and therefore it was selected for clinical evaluation. Patients with advanced solid
tumours against which established treatments had failed, or for which no satisfactory treatment exists and of good performance
status, were eligible. Treatment consisted of twice daily (bd) oral BB-3644 for 84 days. The initial dose was 5 mg bd, and subsequent
cohorts were treated with 10, 20 and 30 mg bd. In all, 22 patients were enrolled. The dose-limiting toxicity (DLT) was
musculoskeletal pain. For 28 days of treatment with BB-3644, 20 mg bd was the maximum tolerated dose (MTD), as at 30 mg bd, six
of nine patients developed significant musculoskeletal toxicity by day 28. Following chronic oral dosing (428 days) with BB-3644,
three of five patients treated at 10 mg bd developed musculoskeletal DLT by day 84, defining the MTD as 5 mg bd. As dose-limiting
musculoskeletal toxicity was encountered at doses of BB-3644 unlikely to provide an advantage over currently available MMPIs,
further evaluation is not recommended.
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There are more than 20 members of the matrix metalloproteinase
(MMP) family of zinc-dependent proteinases, which are involved
in degradation of the extracellular matrix. They have been
implicated in the processes of tumour growth, invasion and
metastasis (Nelson et al, 2000). Inhibition of the MMPs inhibits
tumour cell invasion in vitro, and reduces metastasis formation
after injection of malignant cells in xenograft models (Nelson et al,
2000).
The role of the MMPs in tumour invasion and metastasis
prompted the development of therapeutic strategies targeting
MMPs. Marimastat was the first orally bioavailable MMP inhibitor
(MMPI) to enter clinical testing. Musculoskeletal pain and
inflammation were the treatment-limiting toxicities (Wojtowicz-
Praga et al, 1998; Tierney et al, 1999; Evans et al, 2001).
Cumulative toxicity often necessitated treatment interruption
and subsequent dose reduction or termination of therapy. Phase
I and II studies reported a reduction in the rate of rise of tumour
markers associated with MMPI administration, and an apparent
associated prolongation of survival (Nemunaitis et al, 1998).
Although some authors have reported clinical benefit in associa-
tion with MMPI administration with respect to the reaccumulation
of effusions (Macaulay et al, 1999) or pain (Evans et al, 2001),
randomised studies have shown no evidence of a survival
advantage following MMPI administration (Phuphanich et al,
2001; Bramhall et al, 2002a, b; Shepherd et al, 2002; Rosenbaum
et al, 2003).
Due to the role of MMPs in tumour invasion and metastasis,
there is interest in chronic administration for patients with
minimal residual disease. Attempts have therefore continued to
develop MMPIs with a more favourable toxicity profile than
currently available agents.
BB-3644 was developed as an oral, broad-spectrum MMPI. It is
structurally related to marimastat and BB-94, in that it is a
hydroxamic acid-based metalloproteinase inhibitor. It demon-
strates activity against the different subtypes of MMP ranging
between an IC50 of 3 nM against collagenase-3 to 80 nM against
gelatinase A. It also shows activity against the unrelated
metalloproteinase enkephalinase (IC50 40 nM). It is more than
10-fold more active than marimastat in the inhibition of the
processing of cell-bound TNF-a.
In animal studies, BB-3644 showed activity in inhibiting tumour
growth in a range of tumour models including the MDA-435
human breast carcinoma and B16-BL6 murine melanoma models
(British Biotech, unpublished data). In a model of lung colonisa-
tion by HODP.IP rat mammary carcinoma cells, BB-3644 had
similar antitumour activity to marimastat, but, unlike marimastat,
did not cause tendinitis of the hind limbs (British Biotech,
unpublished data).
Toxicity studies in animals have shown the principal toxicity of
BB-3644 in marmosets and rhesus macaques was cell debris in the
gall bladder, with mucosal erosions and epithelial hyperplasia. In
dogs, ocular changes consisting of conjunctival hyperaemia,
chemosis, corneal stromal limbal vascularisation and diffuse
corneal haze and flocculation were noted. Encephalopathy
occurred at higher doses. In marmosets, BB-3644 induced
inflammation of joint ligaments and tendons (British Biotech,
unpublished data).
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The primary aims of this study were:
K to determine the DLT and maximum tolerated dose (MTD) of
BB-3644 administered on a protracted daily oral dosing
schedule;
K to recommend a dose for further activity studies;
K to evaluate the PK parameters of BB-3644.
The secondary aim of this study was:
K To seek preliminary evidence of antitumour activity and clinical
benefit.
MATERIALS AND METHODS
Study centres
The study was performed at the Cancer Research UK Oncology
Units at the Churchill Hospital, Oxford, England and the Western
General Hospital, Edinburgh, Scotland. The trial was designed to
comply with the ethical principals of Good Clinical Practice in
accordance with the Declaration of Helsinki. The study was
approved by the Medicine and Clinical Oncology Research Ethics
Subcommittee, Lothian Research Ethics Committee (Reference
1999/4/119) and the Oxford Research Ethics Committee (C00.149).
All patients gave written, informed consent prior to study-
screening procedures.
Pretreatment evaluation
Patients were eligible for the study if they had a histologically
proven diagnosis of a solid tumour for which no satisfactory
treatment exists or against which established treatments had failed.
Patients over the age of 18 were required to be of ECOG
performance status 0, 1 or 2, and to have a predicted survival of
at least 3 months.
All patients had satisfactory haematological function, as defined
by a haemoglobin level X10 g dl1, neutrophil count
X1.5 109 l1 and a platelet count X100 109 l1. They also
had to have satisfactory renal and hepatic function, with a serum
creatinine within the normal range (p110 mmol l1) and/or
calculated creatinine clearance X60 ml min1, serum bilirubin
p17 mmol l1 and other liver function tests less than twice the
upper limit of the normal.
Patients with upper gastrointestinal cancers were excluded, as it
was felt that this may alter the pharmacokinetics of an orally
administered drug. Patients with recent ocular surgery were also
excluded. In premenopausal women, pregnancy was excluded and
adequate contraception was required for the duration of treatment
and follow-up.
Study design and treatment
This was a phase I, open-label, dose-escalation study. BB-3644 was
supplied as capsules comprising 5, 10, 20 and 40 mg BB-3644 (with
maize starch, colloidal silica, magnesium stearate and lactose) by
British Biotech Pharmaceuticals Ltd, UK. BB-3644 was adminis-
tered orally twice daily for 84 days to cohorts of patients at doses 5,
10, 20 and 30 mg. Dose escalation was performed in subsequent
cohorts if three patients had been treated at a dose level without
dose-limiting toxicity (DLT) by day 28. Dose-limiting toxicity was
defined as ‘an adverse reaction likely to be caused by the study
drug and unlikely to be attributed to concurrent disease or other
drugs or chemicals’. Essentially, any toxicity graded by CTC
criteria as at least grade II was considered to be a DLT, as this
could preclude chronic oral administration of a drug. If one
patient experienced DLT, the cohort size was increased to six
patients for that dose level. Further dose escalation was performed,
provided that no more than two of the six patients experienced
DLT by day 28. Nine patients were to be treated at the highest dose
level. Patients experiencing DLT were eligible to continue
treatment at a reduced dose following resolution of toxicity.
Pharmacokinetics
Blood samples were collected in heparinised tubes before
treatment, every 15 min for 2 h, at 2 h 30 min, 3, 4, 6, 8, 10
and 24 h on days 1 and 14 for the measurement of BB-3644.
Blood samples were kept on ice. They were centrifuged at 41C
(1500 g for 10 min) within 30 min of collection. The supernatant
plasma was collected and frozen at 701C or cooler, until
sent for analysis. Samples were analysed centrally in the
Department of Drug Metabolism and Pharmacokinetics at British
Biotech, UK.
Samples were analysed for BB-3644 content using a validated
reverse-phase HPLC method with mass spectrometric detection.
The limit of quantification was 1 ng ml1. The data were analysed
using WinNonlin v2.1 Standard version (Pharsight Corporation,
USA). PK parameters were derived from individual plasma
concentration–time data, using noncompartmental analysis.
Monitoring
Physical examination, chest radiograph, haematology and serum
chemistry were checked at baseline, every 4 weeks and at study
termination. Abdominal ultrasound scans were performed at the
same times, with particular attention to the gallbladder in view of
the gallbladder lesions found in animal studies. Patients were also
reviewed by an opthalmologist at these times, to check the visual
acuity, visual fields, and examine the whole eye and the fundi.
Disease assessment was performed at baseline and repeated at
84 days or at withdrawal from the study. Patients were reviewed 4
weeks after withdrawal from the study.
RESULTS
Patient demographics
Between November 1999 and March 2001, 22 patients were treated
within the study. One patient entered did not fully meet the
inclusion criteria on the basis of hepatic function, as alkaline
phosphatase and gamma-GT were increased to twice the upper
limit of the reference range, but data from this patient have been
included in the analysis. Two patients had creatinine levels above
that specified in the protocol, but within the normal range of their
local laboratory, and were deemed eligible.
The characteristics of patients within the study are listed in
Table 1. The patients were relatively young (median age 55.5 years,
range 31–71 years). The majority of patients (86%) had previously
received chemotherapy.
Treatment administered
Early dose levels were expanded, as per protocol, due to patient
drop-out before day 28. At 5 mg bd, two patients withdrew within 4
weeks, one due to an adverse event not considered to be related to
the study drug, and one due to disease progression. These patients
were replaced in the study. As these events were not considered to
be related to the study drug, this was not considered to represent
DLT. At 10 mg bd, again patient withdrawal was not considered to
be related to the study drug, so dose escalation continued. At
20 mg bd, all patients completed 28 days of treatment without
experiencing DLT, so the dose was increased to 30 mg bd. At this
dose, two patients received less than 4 weeks of treatment, and so
were replaced. Three other patients were withdrawn before
completion of the 84 days of treatment, two due to adverse events
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and one due to disease progression. For 28 days of treatment with
the drug 20 mg bd was therefore considered to be the MTD.
One patient, treated at 10 mg bd, had stable disease after 84 days
of treatment, and continued the study drug on an extension
protocol. While in the extension phase of the study, she had a
pulmonary embolus, and subsequently further thromboembolic
episodes despite adequate anticoagulation. She died after 250 days
on study, after a probable cerebrovascular infarction with a left-
sided hemiparesis.
One patient in the 30 mg bd group received 20 mg on days 0 and
1, and so, for PK analysis, was included with the 20 mg bd group
on day 0 and with the 30 mg bd group on day 14.
Adverse events and DLTs
There was no significant opthalmological or gall bladder-related
toxicity seen. All patients did, however, experience adverse events
during the study. These were considered to be treatment-related in
three patients at 5 mg bd, five at 10 mg bd, one at 20 mg bd and
eight at 30 mg bd. The most common treatment-related events
were musculoskeletal in nature and were reported for one, three,
one and eight patients, respectively. Recovery from musculoske-
letal toxicity was often delayed, but was not related to the dose,
type of event or NCI CTC grade. At 5–20 mg bd, 94% of
musculoskeletal events resolved, with a median time to resolution
of 175 days. At 30 mg bd, only 78% of events resolved, but the
median time to resolution was 49 days.
The musculoskeletal events were considered dose-limiting in
three patients at 10 mg bd, and six at 30 mg bd (Table 2). The dose
was escalated, according to the protocol, if three patients had been
treated at that dose for 28 days, without experiencing DLT. The
dose was therefore increased, despite the high proportion of
patients experiencing DLTs at early dose levels.
Two patients experienced dose-limiting malaise (NCI CTC
toxicity 4grade 1) on treatment, considered to be possibly related
to the study drug. Two patients developed phlebitis, and one of
these patients subsequently had a deep venous thrombosis and
pulmonary embolism. Again, there was considered to be a possible
relationship to the study drug. Other symptoms considered to be
possibly related to the study medication were taste changes (one
patient), shortness of breath (one patient), neurosensory changes
(one patient) and anorexia (one patient).
Serious adverse events (SAEs) consisted of events requiring
hospitalisation (seven patients) and events resulting in death (two
patients). SAEs were reported for eight patients during the main
study and for a ninth patient during the continuation of treatment.
One SAE was considered to be possibly related to the study drug
(thromboembolic episodes). This was attributed to the drug, on
the basis of the temporal relationship between drug administration
and the development of thromboembolic phenomena. Throm-
boembolic episodes have not previously been reported in relation
to MMPI administration.
All other SAEs were considered to be related to the underlying
malignancy. These consisted of sepsis (one patient); nausea and
vomiting (two patients); hypercalcaemia (two patients); abdominal
pain (two patients) and acute renal failure (one patient).
Assessment of response
Response was formally assessed radiologically after 3 months of
therapy. Of the 13 patients that completed 12 weeks of therapy, two
had stable disease and 11 had progressive disease radiologically.
Three patients completed less than 28 days of therapy, and disease
was therefore deemed nonevaluable. Five patients progressed
clinically and one patient progressed radiologically prior to the 3-
month timepoint. It was therefore concluded that in our study we
had no evidence of beneficial therapeutic activity.
Plasma pharmacokinetics
On the days of PK sampling, only the morning dose of BB-3644
was taken. On day 0, BB-3644 was rapidly absorbed (Figure 1;
Table 1 Patient characteristics
Total patients treated 22
Male/female 13/9
Age (years)
Median 55.5
Range 31–71
WHO performance status
0 6
1 15
2 1
Primary tumour site
Carcinoma (not otherwise specified) 5
Cervical cancer 2
Colorectal cancer 6
Lung cancer 8
Ovarian cancer 1
Previous treatment
Surgery 13
Chemotherapy 19
Radiotherapy 12
Hormone/immuno/biological therapy 2
Table 2 Dose-limiting toxicity
Toxicity within 28 days Toxicity at any time
5 mg bd 1/5 (20%) 1/5 (20.0%)
10 mg bd 0/5 3/5 (60.0%)
20 mg bd 0/3 1/3 (33.3%)
30 mg bd 4/9 (44%) 6/9 (66.7%)
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Figure 1 Mean plasma concentration of BB-3644 on day 0.
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Table 3), achieving a mean maximal concentration between 30 and
90 min following administration. The maximal concentration
achieved was dose-dependent and linear, varying between 58 and
315 ng ml1 for the maximum BB-3644 dose. The initial decline in
plasma concentrations was rapid and elimination was multiphasic,
with BB-3644 detectable 24 h after dosing.
After repeated oral administration (day 14) (Figure 2 and
Table 3), the drug was again rapidly absorbed. The mean
maximum concentration achieved was higher than that on day 1
(134–536 ng ml1).
DISCUSSION
In this phase I study of the novel matrix metalloprotease inhibitor
BB-3644 administered by mouth twice daily, the start dose was
5 mg bd and the dose was escalated to a dose of 30 mg bd, based on
the incidence of toxicities before day 28. Dose escalation
was discontinued at a dose of 30 mg bd, due to the development of
significant musculoskeletal toxicity in six out of nine patients by
day 28.
When treatment was continued beyond 28 days, however,
patients developed DLT at ALL doses of BB-3644. For a 28-day
administration of BB-3644, 20 mg might be considered to be the
MTD. However, it is anticipated that administration of such agents
should be tolerable over longer periods and therefore, for chronic
oral administration, 5 mg bd could have been considered to be the
MTD, as three out of five patients developed DLT at 10 mg bd
within 84 days.
The DLT was musculoskeletal. Musculoskeletal DLTs were
recorded in 14 of the patients (64%). No other DLT was observed
in more than two patients (9% of patients).
PK analysis demonstrated that the BB-3644 was rapidly absorbed
when orally administered and the drug was still identifiable after 24 h.
At the maximum dose of BB-3644, we achieved an AUC of
4401 ng h ml1. In the phase I studies of marimastat, the AUC
achieved at the MTD was 2623 ng h ml1 (Wojtowicz-Praga et al,
1998), which had been our target AUC in this study. The PK
assessment confirmed that our dosing strategy had been appropriate
to achieve adequate plasma exposure of the drug.
It had been hoped that, by virtue of its different biochemical
profile, BB-3644 would be better tolerated than marimastat with
respect to musculoskeletal toxicity. Indeed, preclinical cancer
models and toxicity studies had indicated that an improved
therapeutic margin might be achievable in patients. The toler-
ability of BB-3644 in our study was no better than that reported in
phase I and II studies of marimastat, with a very similar pattern of
musculoskeletal toxicity (Wojtowicz-Praga et al, 1998; Tierney
et al, 1999; Evans et al, 2001).
In view of the toxicity that was experienced at dose levels
associated with similar plasma exposure, it was felt unlikely that
the drug offered any benefit over currently available MMPIs and
clinical development was terminated.
CONCLUSION
Chronic oral administration of BB-3644 in patients with cancer is
associated with musculoskeletal toxicities from doses of 5 mg bd
upwards, and offers no advantage over marimastat in terms of
systemic exposure and tolerability.
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